Global CAR T-Cell Therapy Market Growth (Status and Outlook) 2023-2029

Global CAR T-Cell Therapy Market Growth (Status and Outlook) 2023-2029

Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.

LPI (LP Information)' newest research report, the “CAR T-Cell Therapy Industry Forecast” looks at past sales and reviews total world CAR T-Cell Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected CAR T-Cell Therapy sales for 2023 through 2029. With CAR T-Cell Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CAR T-Cell Therapy industry.

This Insight Report provides a comprehensive analysis of the global CAR T-Cell Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CAR T-Cell Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CAR T-Cell Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CAR T-Cell Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CAR T-Cell Therapy.

The global CAR T-Cell Therapy market size is projected to grow from US$ 1683.2 million in 2022 to US$ 2184.8 million in 2029; it is expected to grow at a CAGR of 3.8% from 2023 to 2029.

The global top three CAR T-Cell therapy players include Novartis, Gilead Sciences, Bristol-Myers Squibb, with a total market share of more than 99%. The largest player is Gilead Sciences, with a market share of over 50%. North America is the global most important consumer market for CAR T-Cell therapy, with a market share of more than 65%. In terms of type, CD19-targeted CAR cell therapy has a market share of over 90%. In the field of application, the market share of lymphoma exceeds 90%.

This report presents a comprehensive overview, market shares, and growth opportunities of CAR T-Cell Therapy market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Allogeneic
Autologous

Segmentation by application
Hospitals
Cancer Research Centers
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Celgene (Juno Therapeutics)
Novartis
Gilead (Kite Pharma)
Pfizer
CARsgen Therapeutics
Autolus Therapeutics
Aurora BioPharma
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Collectis
Allogene Therapeutics
Celyad

Please note: The report will take approximately 2 business days to prepare and deliver.